MDDA would like to congratulate HemoShear Therapeutics who have received approval to go into phase 2 of their clinical trial for the treatment of patients with methylmalonic acidemia (MMA) and propionic acidemia (PA). This is very exciting news and we would like to say thank you on behalf of all of the Australian Families for the development of this potential life changing life changing treatment. To read more about HemoShear’s phase 2 clinical trial you can click here.